Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Major Shareholder Sells $1,019,946.50 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) major shareholder Portage Biotech Inc. sold 35,650 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $28.61, for a total transaction of $1,019,946.50. Following the transaction, the insider now owns 124,371 shares of the company’s stock, valued at $3,558,254.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Portage Biotech Inc. also recently made the following trade(s):

  • On Friday, January 5th, Portage Biotech Inc. sold 22,996 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $30.03, for a total transaction of $690,569.88.
  • On Tuesday, January 9th, Portage Biotech Inc. sold 84,881 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $30.06, for a total value of $2,551,522.86.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded down $0.96 during mid-day trading on Thursday, hitting $26.13. 435,016 shares of the stock were exchanged, compared to its average volume of 375,302. The company has a market cap of $975.72 and a PE ratio of -5.01. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $17.00 and a one year high of $39.51.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP bought a new position in Biohaven Pharmaceutical in the 3rd quarter valued at about $302,000. Perceptive Advisors LLC bought a new position in Biohaven Pharmaceutical in the 3rd quarter valued at about $11,443,000. Janus Henderson Group PLC bought a new position in Biohaven Pharmaceutical in the 3rd quarter valued at about $25,751,000. VHCP Management II LLC bought a new position in Biohaven Pharmaceutical in the 3rd quarter valued at about $60,826,000. Finally, Nicholas Investment Partners LP bought a new position in Biohaven Pharmaceutical in the 3rd quarter valued at about $3,602,000. 47.76% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on BHVN. BidaskClub upgraded Biohaven Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 28th. Needham & Company LLC restated a “buy” rating and issued a $36.00 price objective on shares of Biohaven Pharmaceutical in a report on Wednesday, November 15th. William Blair restated an “outperform” rating on shares of Biohaven Pharmaceutical in a report on Tuesday, October 3rd. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, Canaccord Genuity began coverage on Biohaven Pharmaceutical in a report on Friday, December 15th. They issued a “buy” rating and a $30.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. Biohaven Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $36.14.

TRADEMARK VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/biohaven-pharmaceutical-holding-co-ltd-bhvn-major-shareholder-portage-biotech-inc-sells-35650-shares.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply